Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Mexico Precision Medicine Market Size, Share, Trends, and Forecast 2026-2034 | Genomics and Digital Health to Drive 7.97% CAGR, Reaching USD 2.72 Billion

GlobeNewswire

Dublin, Oct. 21, 2026 -- "Mexico Precision Medicine Market Size, Share, Trends and Forecast by Product, Technology, Application, End User, and Region, 2026-2034" has been added to ResearchAndMarkets.com's offering.

The Mexico precision medicine market reached USD 1.33 billion in 2025 and is projected to reach USD 2.72 billion by 2034. According to the report, the market is expected to expand at a compound annual growth rate (CAGR) of 7.97% during 2026-2034. Growth is being supported by advances in genomics, increasing adoption of digital health technologies, expanding healthcare infrastructure, and rising demand for personalized treatment strategies.

Precision medicine is gaining momentum across Mexico as healthcare providers, research institutions, pharmaceutical companies, and biotechnology organizations invest in targeted approaches to disease diagnosis, prevention, and treatment. Oncology, pharmacogenomics, chronic disease care, and rare disease management represent important areas of application, while stronger clinical data capabilities are supporting broader implementation throughout the healthcare system.

Mexico Precision Medicine Market Trends

Advancements in Genomic Research and Technologies

Mexico has made significant progress in genomic research through continued investment in biotechnology, academic programs, medical research institutions, and sequencing capabilities. More affordable sequencing technologies are enabling researchers to identify genetic variations associated with the Mexican population, supporting patient-tailored testing and therapy development.

Public and private organizations are also advancing biobanks, genome mapping programs, and international research partnerships. These initiatives are contributing to the identification of population-specific disease markers related to cancer, diabetes, and other conditions. As sequencing costs decline and genomic testing becomes more accessible, healthcare providers are better positioned to select targeted treatments and incorporate genomic information into clinical decision-making.

Increasing Burden of Chronic and Genetic Diseases

The rising prevalence of cardiovascular disease, cancer, diabetes, and hereditary disorders is strengthening demand for personalized care in Mexico. Treatment strategies informed by genetic profiles, lifestyle factors, and environmental data can improve clinical outcomes while reducing the risk of adverse drug reactions.

Genetic testing is also supporting earlier diagnosis, risk assessment, and preventive care for hereditary conditions. Growing awareness among patients and clinicians, combined with the need for more effective chronic disease management, is expected to accelerate the adoption of precision medicine solutions across hospitals, clinics, and diagnostic centers.

Expansion of Digital Health and Data Infrastructure

Electronic health records, health information systems, big data analytics, and connected care platforms are becoming increasingly important to the Mexico precision medicine market. These technologies support the secure collection and analysis of genetic, clinical, and lifestyle data required for personalized care programs.

Artificial intelligence and machine learning applications are helping healthcare organizations identify disease patterns, predict treatment responses, and improve clinical decision-making. Telemedicine platforms and mobile health applications are also extending access to specialized services, including in remote and underserved areas. Continued improvements in digital infrastructure and system interoperability are expected to make precision medicine more scalable and efficient.

Market Segmentation

The report analyzes the Mexico precision medicine market by product, technology, application, end user, and region, with forecasts covering 2026-2034.

  • Product: Consumables, instruments, and services
  • Technology: Big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others
  • Application: Oncology, central nervous system (CNS), immunology, respiratory medicine, infections, and others
  • End user: Hospitals and clinics, diagnostic centers, pharma and biotech companies, healthcare IT firms, and others
  • Region: Northern Mexico, Central Mexico, Southern Mexico, and others

These segments reflect the diverse technologies and clinical settings contributing to market expansion. Consumables, instruments, and services support laboratory and clinical workflows, while bioinformatics, sequencing, analytics, and companion diagnostics enable more precise therapeutic selection. Hospitals and clinics remain central to patient care, with diagnostic centers, pharma and biotech companies, and healthcare IT firms contributing specialized capabilities.

Competitive Landscape

The report evaluates the competitive structure of the Mexico precision medicine market, including key player positioning, leading strategies, company performance, and market development priorities. Detailed company profiles provide insight into the capabilities and strategic direction of major participants.

The analysis also examines market performance, future growth prospects, value chain stages, competitive intensity, key challenges, and the factors shaping adoption. Overall, sustained investment in genomic science, digital health, clinical infrastructure, and personalized therapeutics is expected to create significant opportunities for precision medicine stakeholders in Mexico through 2034.

Report AttributeDetails
No. of Pages119
Forecast Period2025 - 2034
Estimated Market Value (USD) in 2025$1.33 Billion
Forecasted Market Value (USD) by 2034$2.72 Billion
Compound Annual Growth Rate8.2%
Regions CoveredMexico

Key Topics Covered:

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Mexico Precision Medicine Market - Introduction
4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Mexico Precision Medicine Market Landscape
5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Mexico Precision Medicine Market - Breakup by Product
6.1 Consumables
6.2 Instruments
6.3 Services
6.4 Product Segment Analysis
6.4.1 Overview
6.4.2 Historical and Current Market Trends (2020-2025)
6.4.3 Market Forecast (2026-2034)

7 Mexico Precision Medicine Market - Breakup by Technology
7.1 Big Data Analytics
7.2 Bioinformatics
7.3 Gene Sequencing
7.4 Drug Discovery
7.5 Companion Diagnostics
7.6 Others
7.7 Technology Segment Analysis
7.7.1 Overview
7.7.2 Historical and Current Market Trends (2020-2025)
7.7.3 Market Forecast (2026-2034)

8 Mexico Precision Medicine Market - Breakup by Application
8.1 Oncology
8.2 Central Nervous System (CNS)
8.3 Immunology
8.4 Respiratory Medicine
8.5 Infections
8.6 Others
8.7 Application Segment Analysis
8.7.1 Overview
8.7.2 Historical and Current Market Trends (2020-2025)
8.7.3 Market Forecast (2026-2034)

9 Mexico Precision Medicine Market - Breakup by End User
9.1 Hospitals and Clinics
9.2 Diagnostic Centers
9.3 Pharma and Biotech Companies
9.4 Healthcare IT Firms
9.5 Others
9.6 End User Segment Analysis
9.6.1 Overview
9.6.2 Historical and Current Market Trends (2020-2025)
9.6.3 Market Forecast (2026-2034)

10 Mexico Precision Medicine Market - Breakup by Region
10.1 Northern Mexico
10.2 Central Mexico
10.3 Southern Mexico
10.4 Others
10.5 Regional Analysis
10.5.1 Overview
10.5.2 Historical and Current Market Trends (2020-2025)
10.5.3 Market Breakup by Product
10.5.4 Market Breakup by Technology
10.5.5 Market Breakup by Application
10.5.6 Market Breakup by End User
10.5.7 Key Players
10.5.8 Market Forecast (2026-2034)

11 Mexico Precision Medicine Market - Competitive Landscape
11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players
12.1 Business Overview
12.2 Products Offered
12.3 Business Strategies
12.4 SWOT Analysis
12.5 Major News and Events

13 Mexico Precision Medicine Market - Industry Analysis
13.1 Drivers, Restraints, and Opportunities
13.1.1 Overview
13.1.2 Drivers
13.1.3 Restraints
13.1.4 Opportunities
13.2 Porters Five Forces Analysis
13.2.1 Overview
13.2.2 Bargaining Power of Buyers
13.2.3 Bargaining Power of Suppliers
13.2.4 Degree of Competition
13.2.5 Threat of New Entrants
13.2.6 Threat of Substitutes
13.3 Value Chain Analysis

14 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/518a3n

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  1. FinanceCrown Castle Reports Third Quarter 2026 Results and Updates Outlook for Full Year 2026Companies: Crown CastleCrown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the third quarter ended September 30, 2026, and updated its full year 2026 Outlook, as reflected in the table below.
  2. FinanceForge Nano to Trade on NASDAQ as NANO After Completing Business Combination with Archimedes Tech SPAC Partners II Co.Forge Nano, Inc., a leading U.S.-based semiconductor equipment and advanced materials company pioneering Atomic Layer Deposition (“ALD”) technology for artificial intelligence (“AI”)-era chip manufacturing and defense battery applications, today announced the completion of its previously announced business combination following an extraordinary general meeting of Archimedes Tech SPAC Partners II Co. (“Archimedes II”) (NASDAQ: ATII) on October 16, 2026. The combined company will operate as Forge Nano Holdings, Inc. and its common stock and warrants are expected to commence trading on the NASDAQ under the ticker symbols “NANO” and “NANOW,” respectively, on October 22, 2026.
  3. FinanceEagle Bancorp, Inc. Announces Third Quarter 2026 ResultsEagle Bancorp, Inc. ("Eagle" or the "Company") (NASDAQ: EGBN), the Bethesda-based holding company for EagleBank (the "Bank"), one of the largest community banks in the Washington D.C. area, reported its unaudited results for the third quarter ended September 30, 2026.
  4. FinanceFrequency Electronics, Inc.Frequency Electronics Announces Chief Financial Officer Transition; Reaffirms Fiscal 2029 Financial TargetsToday, Frequency Electronics, Inc. (Nasdaq: FEIM) (“FEI” or the “Company”) announced the election of Allen Kaplan as its new Chief Financial Officer (CFO), effective November 1, 2026. As CFO, Mr. Kaplan will join the Company’s senior executive leadership team and will report directly to President and Chief Executive Officer (CEO) Tom McClelland.
  5. FinanceESCO Technologies Announces Fourth Quarter 2026 Earnings Release and Conference CallESCO Technologies Inc. (NYSE:ESE) will report its fourth quarter financial results after the market close on Thursday, November 19, 2026, followed by a conference call where the financial results and related commentary will be discussed.
  6. FinanceJohn B. Sanfilippo & Son, Inc. 1st Quarter Fiscal Year 2027 Operating Results Conference CallJohn B. Sanfilippo & Son, Inc. (NASDAQ: JBSS), a major processor and distributor of snack and recipe nut products and snack bar manufacturer, will hold its quarterly conference call to discuss its first quarter Fiscal 2027 operating results on Thursday, October 29, 2026 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). First Quarter Results are expected to be released after the market closes on Wednesday October 28, 2026.